Name: Latest research reports of Alivus Life Sciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer

936.9000 -7.80 (-0.83%)

NSE Sep 12, 2025 15:31 PM

29.83% Fall from 52W High

Volume: 33,281

Alivus Life Sciences Ltd.

29 Apr 2023

936.90

-0.83%

Glenmark Life Sciences (BUY): All-round beat

Buy: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API

Alivus Life Sciences Ltd. is trading below all available SMAs